Suppression of cortical spreading depression in migraine prophylaxis

Annals of Neurology

Volumn 59, Issue 4, 2006, Pages 652-661

  Ayata, Cenk ^a   Jin, Hongwei ^a   Kudo, Chiho ^a   Dalkara, Turgay ^b   Moskowitz, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METHYSERGIDE; POTASSIUM; PROPRANOLOL; SEROTONIN AGONIST; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; EVOKED RESPONSE; MIGRAINE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SPREADING CORTICAL DEPRESSION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ELECTRIC STIMULATION; MALE; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PHYSICAL EXAMINATION; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; SPREADING CORTICAL DEPRESSION; TIME FACTORS;

EID: 33645789260     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20778     Document Type: Article

References (78)

1. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762.
2. Rabkin R, Stables DP, Levin NW, Suzman MM. The prophylactic value of propranolol in angina pectoris. Am J Cardiol 1966;18:370-383.
3. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-973.
4. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-390.
5. Kunkler PE, Kraig RP. Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus 2003;13:835-844.
6. Lauritzen M, Jorgensen MB, Diemer NH, et al. Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol 1982;12:469-474.
7. Leao A, Morison R. Propagation of spreading cortical depression. J Neurophysiol 1945;8:33-45.
8. Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr Clin Neurophysiol Suppl 1958;10:705.
9. Cao Y, Welch KM, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999;56:548-554.
10. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692.
11. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-1177.
12. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142.
13. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984;16:157-168.
14. Werhahn KJ, Wiseman K, Herzog J, et al. Motor cortex excitability in patients with migraine with aura and hemiplegic migraine. Cephalalgia 2000;20:45-50.
15. Lang E, Kaltenhauser M, Neundorfer B, Seidler S. Hyperexcitability of the primary somatosensory cortex in migraine - a magnetoencephalographic study. Brain 2004;127:2459-2469.
16. van der Kamp W, MaassenVanDenBrink A, Ferrari MD, van Dijk JG. Interictal cortical excitability to magnetic stimulation in familial hemiplegic migraine. Neurology 1997;48:1462-1464.
17. Bohotin V, Fumal A, Vandenheede M, et al. Effects of repetitive transcranial magnetic stimulation on visual evoked potentials in migraine. Brain 2002;125:912-922.
18. Coppola G, Vandenheede M, Di Clemente L, et al. Somatosensory evoked high-frequency oscillations reflecting thalamocortical activity are decreased in migraine patients between attacks. Brain 2005;128:98-103.
19. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacnala knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41:701-710.
20. Ayata C, Shimizu-Sasamata M, Lo EH, et al. Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the alpha1A subunit of P/Q type calcium channels. Neuroscience 2000;95:639-645.
21. Richter F, Mikulik O, Ebersberger A, Schaible HG. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat - a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J Cereb Blood Flow Metab 2005;25:1225-1235.
22. Phillis JW, Ochs S. Excitation and depression of cortical neurones during spreading depression. Exp Brain Res 1971;12:132-149.
23. Martin H, Warner DS, Todd MM. Effects of glycine receptor antagonism on spreading depression in the rat. Neurosci Lett 1994;180:285-289.
24. Reid KH, Marrannes R, De Prins E, Wauquier A. Strength-duration properties of cathodal pulses eliciting spreading depression in rat cerebral cortex. Brain Res 1987;404:361-364.
25. Bures J. Electrotonic mechanisms in activity of central nervous system: production of spreading depression of EEG activity by electrotonus. Physiol Bohemoslov 1954;3:272-287.
26. Amano K, Hamada K, Yagi K, Seino M. Antiepileptic effects of topiramate on amygdaloid kindling in rats. Epilepsy Res 1998;31:123-128.
27. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004;46:1097-1104.
28. Krupp E, Loscher W. Anticonvulsant drug effects in the direct cortical ramp-stimulation model in rats: comparison with conventional seizure models. J Pharmacol Exp Ther 1998;285:1137-1149.
29. Ghelardini C, Galeotti N, Bartolini A. Antinociception induced by amitriptyline and imipramine is mediated by alpha2A-adrenoceptors. Jpn J Pharmacol 2000;82:130-137.
30. Smits JF, van Essen H, Struyker-Boudier HA. Is the antihypertensive effect of propranolol caused by an action within the central nervous system? J Pharmacol Exp Ther 1980;215:221-225.
31. Coimbra NC, Castro-Souza C, Segato EN, et al. Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res 2001;888:314-320.
32. Ferrara JJ, Westervelt CL, Kukuy EL, et al. Burn edema reduction by methysergide is not due to control of regional vasodilation. J Surg Res 1996;61:11-16.
33. Gold LH, Koob GF. Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol Biochem Behav 1988;29:645-648.
34. Kikta DC, Barney CC, Threatte RM, et al. On the mechanism of serotonin-induced dipsogenesis in the rat. Pharmacol Biochem Behav 1983;19:519-525.
35. Lin HQ, Jackson DM, Atrens DM, et al. Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res 1997;744:351-357.
36. Nabeshima T, Ishikawa K, Yamaguchi K, et al. Phencyclidine-induced head-twitch response in rats treated chronically with methysergide. Eur J Pharmacol 1987;133:319-328.
37. Tfelt-Hansen P. Efficacy of beta-blockers in migraine. A critical review. Cephalalgia 1986:6(suppl 5):15-24.
38. Skelton JL, Gardner-Medwin AR, George SA. The effects of carbon dioxide, oxygen and pH on spreading depression in the isolated chick retina. Brain Res 1983;288:229-233.
39. Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;40:792-795.
40. Jin H, Kudo C, Dalkara T, et al. Suppression of cortical spreading depression in migraine prophylaxis. Program No. 169.21. 2005. Washington, DC: Society for Neuroscience, 2005.
41. Smith MI, Read SJ, Chan WN, et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000;20:546-553.
42. Wiedemann M, de Lima VM, Hanke W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch Pharmacol 1996;353:552-556.
43. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 1994;34:30-35.
44. Hansen A, Lauritzen M, Tfelt-Hansen P. Spreading cortical depression and antimigraine drugs. In: Amery WK, Van Nueten JM, Waquier A, eds. The pharmacological basis of migraine therapy. London: Putman, 1984:161-170.
45. Gemperle AY, Enz A, Pozza MF, et al. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 2003;117:681-695.
46. Kornhuber J, Schultz A, Wiltfang J, et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999;156:885-890.
47. Tsuneizumi T, Babb SM, Cohen BM. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 1992;32:817-824.
48. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-495.
49. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 1999;39:633-643.
50. Bowyer SM, Mason KM, Moran JE, et al. Cortical hyperexcitability in migraine patients before and after sodium valproate treatment. J Clin Neurophysiol 2005;22:65-67.
51. Mulleners WM, Chronicle EP, Vredeveld JW, Koehler PJ. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol 2002;9:35-40.
52. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 2005;45:546-552.
53. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(suppl 1):S52-S60.
54. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(suppl 5):S2-S10.
55. Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002;58:368-372.
56. Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res 2003;55:225-233.
57. Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-359.
58. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001-1011.
59. Muller M, Somjen GG. Na(+) and K(+) concentrations, extra- and intracellular voltages, and the effect of TTX in hypoxic rat hippocampal slices. J Neurophysiol 2000;83:735-745.
60. Sheardown MJ. The triggering of spreading depression in the chicken retina: a pharmacological study. Brain Res 1993;607:189-194.
61. Alves OL, Doyle AJ, Clausen T, et al. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann NY Acad Sci 2003;993:25-34; discussion, 2003;993:48-53.
62. Hanaya R, Sasa M, Ujihara H, et al. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res 1998;789:274-282.
63. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
64. Huang CC, Wang SJ, Gean PW. Selective enhancement of P-type calcium currents by isoproterenol in the rat amygdala. J Neurosci 1998;18:2276-2282.
65. Lynch MA, Bliss TV. Noradrenaline modulates the release of [14C]glutamate from dentate but not from CA1/CA3 slices of rat hippocampus. Neuropharmacology 1986;25:493-498.
66. Sun QQ, Dale N. G-proteins are involved in 5-HT receptor-mediated modulation of N- and P/Q- but not T-type Ca2+ channels. J Neurosci 1999;19:890-899.
67. Kruger H, Heinemann U, Luhmann HJ. Effects of ionotropic glutamate receptor blockade and 5-HT1A receptor activation on spreading depression in rat neocortical slices. Neuroreport 1999;10:2651-2656.
68. Czyrak A, Czepiel K, Mackowiak M, et al. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res 2003;989:42-51.
69. Ishii Y, Sumi T. Amitriptyline inhibits striatal efflux of neurotransmitters via blockade of voltage-dependent Na+ channels. Eur J Pharmacol 1992;221:377-380.
70. Anderson TR, Andrew RD. Spreading depression: imaging and blockade in the rat neocortical brain slice. J Neurophysiol 2002;88:2713-2725.
71. Nedergaard M, Cooper AJ, Goldman SA. Gap junctions are required for the propagation of spreading depression. J Neurobiol 1995;28:433-444.
72. Wu YJ, Boissard CG, Greco C, et al. (S)-N-[1-(3-Morpholin-4-ylphenyl) ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J Med Chem 2003;46:3197-3200.
73. Kunkler PE, Kraig RP. P/Q Ca2+ channel blockade stops spreading depression and related pyramidal neuronal Ca2+ rise in hippocampal organ culture. Hippocampus 2004;14:356-367.
74. Bradley DP, Smith MI, Netsiri C, et al. Diffusion-weighted MRI used to detect in vivo modulation of conical spreading depression: comparison of sumatriptan and tonabersat. Exp Neurol 2001;172:342-353.
75. Peroutka SJ, Snyder SH. Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 1980;215:582-587.
76. Nappi G, Sandrini G, Granella F, et al. A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. Headache 1990;30:439-444.
77. O'Donnell T, Rotzinger S, Ulrich M, et al. Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. Eur Neuropsychopharmacol 2003;13:220-227.
78. Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res Bull 2005;65:331-338.